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he plasma membrane calcium/calmodulin-dependent
calcium ATPase (PMCA) (Shull, G.E., and J. Greeb.
 
1988. 
 
J. Biol. Chem.
 
 263:8646–8657; Verma, A.K.,
A.G. Filoteo, D.R. Stanford, E.D. Wieben, J.T. Penniston, E.E.
Strehler, R. Fischer, R. Heim, G. Vogel, S. Mathews, et al.
1988. 
 
J. Biol. Chem.
 
 263:14152–14159; Carafoli, E. 1997.
 
Basic Res. Cardiol.
 
 92:59–61) has been proposed to be a
regulator of calcium homeostasis and signal transduction
networks of the cell. However, little is known about its
precise mechanisms of action. Knock-out of (mainly
neuronal) isoform 2 of the enzyme resulted in hearing loss
and balance deﬁcits due to severe inner ear defects, affecting
formation and maintenance of otoconia (Kozel, P.J., R.A.
Friedman, L.C. Erway, E.N. Yamoah, L.H. Liu, T. Riddle, J.J.
Duffy, T. Doetschman, M.L. Miller, E.L. Cardell, and G.E.
Shull. 1998. 
 
J. Biol. Chem.
 
 273:18693–18696). Here we
T
 
demonstrate that PMCA 4b is a negative regulator of nitric
oxide synthase I (NOS-I, nNOS) in HEK293 embryonic
kidney and neuro-2a neuroblastoma cell models. Binding of
PMCA 4b to NOS-I was mediated by interaction of the
COOH-terminal amino acids of PMCA 4b and the PDZ
domain of NOS-I (PDZ: PSD 95/Dlg/ZO-1 protein domain).
Increasing expression of wild-type PMCA 4b (but not PMCA
mutants unable to bind PDZ domains or devoid of Ca
 
2
 
 
 
-
transporting activity) dramatically downregulated NO syn-
thesis from wild-type NOS-I. A NOS-I mutant lacking the
PDZ domain was not regulated by PMCA, demonstrating the
speciﬁc nature of the PMCA–NOS-I interaction. Elucidation
of PMCA as an interaction partner and major regulator of
NOS-I provides evidence for a new dimension of integration
between calcium and NO signaling pathways.
 
Introduction
 
In initial attempts to gain insight into the unknown regula-
tory function of the plasma membrane calcium/calmodulin-
 
dependent calcium ATPase (PMCA)* (Carafoli, 1997; Shull
and Greeb, 1988; Verma et al., 1988), we have shown previ-
 
ously that the PMCA is controlled by 
 
 
 
-adrenergic stimulation
 
(Neyses et al., 1985), that it regulated differentiation in a skeletal
muscle cell line (Hammes et al., 1994, 1996), modulated hy-
pertrophic stimuli in the myocardium of transgenic animals
expressing PMCA under the control of the ventricle-specific
myosin light chain-2 promoter, and was not involved in beat-
to-beat regulation of heart contraction (Hammes et al., 1998).
Furthermore, we and others have shown that PMCA 4 is local-
ized to caveolae (Fujimoto, 1993; Hammes et al., 1998),
membrane structures (sometimes also called “signalosomes” or
microdomains) containing a wide variety of effectors of cellular
signal transduction (Sargiacomo et al., 1993; Chang et al.,
1994; Lisanti et al., 1994; Robbins et al., 1995; Schnitzer et al.,
1995; Song et al., 1996a) including nitric oxide synthase
(NOS)-I (Venema et al., 1997; Segal et al., 1999) and the cy-
toskeletal protein dystrophin (Song et al., 1996b). Because
PMCA 4b has recently been shown to bind to members of the
membrane-associated guanylate kinase protein family via their
PDZ domains (Kim et al., 1998), we tested whether it inter-
acts with NOS-I, which has been demonstrated recently to be
part of a multiprotein complex largely organized by PDZ do-
mains (through direct interaction or via adapter proteins;
Brenman et al., 1995, 1996; Hillier et al., 1999) and whether
this interaction was physiologically relevant.
 
Results and discussion
 
Physical interaction of the PMCA and NOS-I was demon-
strated by conventional immunoprecipitation (Fig. 1, D and
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E) as well as glutathione 
 
S
 
-transferase (GST) pull-down as-
says, using the PDZ domain of NOS-I as a bait (Fig. 1 C).
“Capping” the PMCA 4b COOH terminus (carrying the
PDZ domain binding sequence) with an myc/6
 
 
 
His tag re-
sulted in a loss of physical interaction (Fig. 1 D). Expression
of wild-type NOS-I and deletion constructs (overview in
Fig. 1 A) was confirmed by Western blotting (Fig. 1 B). This
established that PMCA 4b and NOS-I interact physically,
either directly or through unknown adapters. Full-length
PMCA 4b interacted with purified GST–PDZ fusion pro-
tein, directly demonstrating specificity of interaction with
the PDZ domain (Fig. 1 C). Similar interaction of PMCA
and NOS-I was also observed in extracts of rat brain. Using
PMCA-specific antibodies 5F10 and 2A, NOS-I was also
coprecipitated from rat brain extracts (Fig. 1 F).
In a simple working model, a PMCA molecule interacting
with NOS-I might reduce the local calcium concentration,
leading to reduced activity of NOS-I, a calcium/calmodulin-
dependent isoform of NOS. This hypothesis was tested us-
ing HEK293 cells transfected with expression constructs
shown schematically in Fig. 1 A. Increasing PMCA 4b ex-
pression reduced NOS-I–dependent cGMP dramatically in
a dose-dependent manner (Fig. 2 A, black columns). The
model also predicts that it is the calcium transport function
of the PMCA rather than some other yet unknown module
of the molecule that regulates NOS-I activity: Asp
 
672
 
→
 
Glu
point mutation has been shown previously to render PMCA
almost (but not totally) inactive with respect to its ATPase
and Ca
 
2
 
 
 
-transporting activity (reduction of calcium trans-
port activity by 
 
 
 
90%; Adamo et al., 1995). As predicted,
this mutation resulted in a strong reduction of inhibition of
NOS-I (Fig. 2 A, grey columns) compared with wild-type
PMCA cotransfections (Fig. 2 A, black columns).
To test whether binding of PMCA 4b to the complex via
PDZ domains was a prerequisite for its regulatory action, a
constitutively active mutant of the pump (“ct120”) with a
deletion of both the autoinhibitory and the COOH-termi-
nal PDZ domain binding motif (Enyedi et al., 1993) was
Figure 1. Schematic overview of con-
structs used, expression of NOS-I con-
structs in HEK293 cells, and physical 
interaction of PMCA with NOS-I. (A) 
Plasmid constructs used in transfection 
assays. pCMV–PMCA 4b contains the 
wild-type human PMCA 4b cDNA under 
the control of the CMV promoter. 
pCMV–PMCA 4bmut carries a mutation 
Asp
672→Glu, thereby reducing the 
ATPase activity to  10% (Adamo et al., 
1995). In pCMV–hPMCA 4b cap the 
stop codon is mutated and the myc/
6 His tag is added in frame, resulting in 
capping of the PDZ-binding COOH-
terminal amino acids. NOS-I and NOS-III 
are also under the control of the CMV 
promoter, in pCMV- NOS-I the interact-
ing PDZ domain is deleted. (B) NOS-I was 
expressed in pCMV-NOS-I–transfected 
HEK293 cells, rat brain homogenate 
served as control.  NOS-I was ex-
pressed at comparable levels, the size 
difference is due to deletion of the PDZ 
domain. In untransfected HEK cells, 
NOS-I was undetectable. (C) GST pull-
down assay (Brenman et al., 1995) 
demonstrating specific interaction of 
PMCA 4b with PDZ domain of NOS-I. 
Lysate of pCMV-hPMCA4b–transfected 
HEK293 cells was used as expression 
control (first lane), GST alone did not 
bind PMCA (second lane), whereas 
GST–PDZ fusion protein was able to 
bind PMCA 4b (last lane). (D) NOS-I–
PMCA 4b interaction in cotransfected HEK293 cells. In the first lane NOS-I coprecipitation by a hPMCA 4b–specific antibody (JA3) from 
lysates of cotransfected cells is shown. In the third lane, lysates of NOS-I/PMCA–transfected cells were used as expression controls. Irrelevant 
antibody (anti-FLAG) or protein G beads alone showed no binding of NOS-I (second and fourth lane). Cotransfection with pCMV–hPMCA 4b 
cap, containing an additional COOH-terminal Myc/6 His epitope, prevented interaction of PMCA and NOS-I (penultimate lane), although 
NOS-I was present in the cells (last lane). (E) Coimmunoprecipitation using NOS-I–specific antibodies. The NOS-I–specific polyclonal anti-
body (ABR) coprecipitated the PMCA from lysates of cotransfected HEK293 cells (lane 4). Negative controls: unlabeled beads (lane 1), beads 
plus irrelevant antibodies (lane 2). Positive controls: calmodulin-coated beads (CaM beads, lane 3), anti-PMCA–specific coated beads (with 
polyclonal antibody “2A,” lane 5, and lysates of hPMCA 4b–transfected HEK293 cells (lane 6). (F) Immunoprecipitation using rat brain 
extracts and different PMCA-specific antibodies demonstrating interaction of PMCA and NOS-I in brain. Antibodies specific for NOS-I 
(lane 3), PMCA (monoclonal, clone 5F10, lane 4, rabbit polyclonal “2A”, lane 5), as well as calmodulin beads (CaM beads, lane 2) were 
capable of precipitating NOS-I from rat brain extracts. First lane, control using irrelevant antibodies; last lane, rat brain extract (input). 
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cotransfected with NOS-I. No regulation of NOS activity
by this construct was observed (Fig. 2 A, last column). An
NOS-I mutant carrying a deletion of the PDZ domain
showed no regulation by PMCA 4b (Fig. 2 B). Endothelial
NOS (eNOS or NOS-III) is also regulated by calcium/cal-
modulin, but carries no PDZ domain, and we have been un-
able to coprecipitate NOS-III with PMCA (not shown). In
keeping with the absence of a physical interaction between
PMCA 4b and NOS-III, the activity of this enzyme was not
regulated by PMCA 4b (Fig. 2 C).
The potential physiological relevance of NOS-I regulation
by PMCA 4b was tested in neuro-2a neuroblastoma cells, a
commonly used model system in neuronal biology (Olmsted
et al., 1970). Similarly to HEK293 cells, tight functional
coupling of PMCA4b and NOS-I was observed: NOS-I ac-
tivity was strongly downregulated by the PMCA4b (Fig. 3
A). This effect was reversed by the NO donor NOC-18
(2,2
 
 
 
-[hydroxynitrosohydrazino]bis-ethanamine), suggesting
Figure 2. Functional interaction of PMCA 4b and NOS-I. 
(A) Dose-dependent inhibition of NOS activity by PMCA 4b. Back-
ground cGMP production in untransfected HEK293 cells was set 
as one (first column), induced cGMP production is shown as fold 
increase of cGMP levels in relation to protein content of cell 
lysates. PMCA overexpression showed no effect on cGMP 
production (second column), whereas NOS-I expression resulted 
in an  60-fold increase in cGMP levels (third column). Increasing 
amounts of PMCA led to a dose-dependent reduction of NOS-I 
activity, insertion of the point mutation Asp
672→Glu in the PMCA 
reduced inhibition dramatically (PMCAmut, grey columns). The 
 10-fold higher amounts of mutant PMCA necessary to inhibit 
NOS-I are in line with the fact that the mutation abolishes  90% 
of Ca
2  transport activity (Adamo et al., 1995). Transfection with 
pPMCAmut alone had no effect on cGMP production (column 12), 
treatment of NOS-I transfected cells with L-NAME (L -nitro-L-arginine 
methyl ester; 1 mM) resulted in the expected complete inhibition 
of cGMP production (penultimate column). Coexpression of the 
constitutively active mutant of PMCA 4b (“ct120”, last column) 
did not result in inhibition of NOS-I (n   16, mean  SEM, asterisk 
indicates P   0.05 PMCA vs. PMCAmut). Representative Western 
blots demonstrated expression of relevant proteins: antibody JA3 
showed expression of hPMCA4b and hPMCA4bmut, antibody 
5F10, specific for a more NH2-terminal epitope of PMCAs, demon-
strated expression of PMCA4b(ct120), parallel to constant NOS-I 
expression in cotransfected cells. (B) Deletion of PDZ domain of 
NOS-I ( NOS-I) results in comparable NOS-I activity and com-
plete loss of regulation by increasing amounts of wild-type 
hPMCA 4b (n   16, mean  SEM, changes in fold induction not 
significant). (C) NOS-III expression results in a highly increased 
production of cGMP, too, but this NO-dependent cGMP produc-
tion was not inhibited by wild-type PMCA. The NOS inhibitor 
L-NAME (L-N) abolished cGMP production, proving the NOS-III–
dependent cGMP production (n   2   8, mean   SEM, changes 
in fold induction not significant).
Figure 3. (A) Dose-dependent inhibition of NOS-I activity in 
neuro-2a cells. Coexpression of increasing amounts of PMCA 4b 
and constant levels of NOS-I resulted in a dose-dependent inhibi-
tion of NOS-I activity, comparable to the effects observed in 
HEK293 cells. In this cellular system smaller amounts of PMCA 
( 0.5  g transfected plasmid) were sufficient to obtain maximum 
inhibition of NOS-I, suggesting that an upper limit of PMCA 
expression is reached earlier in this cellular system (n   10, mean 
 SEM, asterisk indicates P   0.01). (B) Representative Western blot 
demonstrating constant NOS-I expression despite dose-dependent 
expression of PMCA 4b in transfected neuro-2a cells. 
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that interaction of these proteins not only occurs in
HEK293 cells, but also in a neuroblastoma-derived cell line.
These results show that the plasma membrane calmodu-
lin-dependent calcium pump 4b is an interaction partner
and a major regulator of neuronal NOS-I and also that this
regulation very likely is of physiological relevance. The stra-
tegic localization to caveolae (Fujimoto, 1993; Hammes et
al., 1998) also suggests that local control of calcium and/or
NO might have further regulatory effects in caveolae-medi-
ated signal transduction.
The pivotal role of NOS-I in neuronal tissue is well estab-
lished, exemplified by the observation that NOS-I deficiency
leads to reduced susceptibility to cerebral ischemic damage
(Huang et al., 1994). Its function in other excitable cells has
been extensively characterized in recent years (Christopherson
and Bredt, 1997). In contrast, the specific role of the PMCA,
beyond the general concept of a calcium transporter, has been
elusive. Our present results assign a function to isoform PMCA
4b, i.e., regulation of NOS-I activity. In a simple model (see
Fig. 4), NOS-I, a Ca
 
2
 
 
 
/calmodulin-dependent isoform of
NOS, is regulated by the PMCA through adjustment of local
calcium concentration. Both interact either directly or through
an adapter protein via the PDZ domain of NOS-I and the
COOH-terminal amino acids of PMCA 4b. Our results are in
line with two previous reports showing the interaction of
COOH-termini of different PMCA “b” splice variants (PMCA
2b and 4b) with PDZ domains and PDZ domain containing
proteins of the MAGUK (membrane-associated guanylate ki-
nase) protein family, whereas the splice variants 2a and 4a failed
to bind to PDZ domains (Kim et al., 1998; DeMarco and
Strehler, 2001). Indeed, it is conceivable that the predominantly
neuronal isoform 2b regulates NOS-I in the context of (at least
some specialized) neurones in vivo. This important issue will
need to be addressed in further studies. These results and the re-
duced inhibition of NOS-I activity by the mutated PMCA
(PMCAmut, Fig. 2, in which the Ca
 
2
 
 
 
-transporting and
ATPase activity are reduced) strongly suggest that it is the cal-
cium transport function of the PMCA which affects regulation
of NOS-I. However, it cannot be entirely excluded that the
COOH-terminal peptide of the PMCA 4b, interacting with
the PDZ domain of NOS-I, mediates inhibition directly; in
this case one would have to postulate that the PMCAmut
(Asp
 
672
 
 mutation) undergoes a conformational change condu-
cive to reduced interaction with NOS-I. A definitive answer to
this and other unlikely possibilities may have to await direct
measurements of calcium concentrations in the vicinity of the
pump which is currently not possible.
The coupling of interaction and function of the two
proteins is in close analogy to the observation that loss of
the PDZ-binding COOH-termini of NMDA receptors
results not only in loss of interaction, but also in complete
loss of receptor function (Sprengel et al., 1998). Different
PMCA isoforms and their splice variants (overview in
Strehler and Zacharias, 2001) are expressed ubiquitously
and NOS-I is a widespread isoform of NOS in neurons
and in excitable tissues (Christopherson and Bredt, 1997).
Therefore, the physical and functional interaction of
PMCA isoforms and NOS-I or other PDZ domain–con-
taining proteins is most likely relevant in a large variety of
cells. These enzymes may define a modular signal trans-
 
duction system which subserves different functions in dif-
ferent cellular contexts.
 
Materials and methods
 
Immunoprecipitations and GST pull-downs
 
Samples were lysed in RIPA buffer (1
 
 
 
 PBS containing 1% Igepal CA-
630, 0.5% sodium deoxycholate, 0.1% SDS and Complete
 
TM
 
 protease in-
hibitor (Roche Diagnostics). Debris was removed by centrifugation
(10,000 
 
g
 
, 5 min, 4
 
 
 
C). After a preclearing step with 0.5 
 
 
 
g irrelevant
antibody (anti-FLAG epitope, Neomarkers) and 25 
 
 
 
l of protein G–Seph-
arose
 
TM
 
 (
 
 
 
50% slurry; Amersham Pharmacia Biotech) 500 
 
 
 
g remaining
protein lysate was coincubated together with 3 
 
 
 
g of precipitating anti-
bodies (polyclonal rabbit anti–NOS-I, Affinity Bioreagents catalog no.
PA3-032A; monoclonal mouse anti-hPMCA4b, clone JA3; and mono-
clonal mouse anti-PMCA, clone 5F10, Neomarkers, catalog no. MS-
1305-P1 and MS-1304-P1; polyclonal rabbit anti-hPMCA4b was gener-
ated using a peptide spanning the 15 COOH-terminal amino acids of the
PMCA4b; polyclonal rabbit anti-PMCA (“2A”) was a gift from D. Guerini,
ETH Zürich, Switzerland) and 25 
 
 
 
l protein G–Sepharose
 
TM
 
 at 4
 
 
 
C for 2 h.
Calmodulin-Sepharose beads (CaM beads; Amersham Pharmacia Bio-
tech) served as control. After washing four times with RIPA buffer (see
above) beads were resuspended in 100 
 
 
 
l sample buffer and boiled. 20
 
 
 
l of each sample was loaded and 5 
 
 
 
g (1/100 input) protein extract
served as control. NOS-I was detected using a monoclonal antibody
(clone “16”; Transduction Laboratories, catalog no. N31020) in a dilu-
tion of 1:1,000, and transfected hPMCA4b was detected using the PMCA
4 isoform-specific antibodies JA3 (1:1,000; Figs. 1, C and E, 2 A, and 3 B)
and 5F10 (dilution 1:1,000, Neomarkers), necessary to detect appropri-
ate expression of PMCA(ct120). Immunodetection of proteins on mem-
brane was done using the ECL
 
TM
 
 system according to the manufacturers
protocol (Amersham Pharmacia Biotech).
GST pull-down assays were performed using purified GST-PDZ (NOS-I)
fusion protein, containing the PDZ domain of NOS-I (Brenman et al.,
1995, 1996) bound to glutathione-Sepharose
 
TM
 
 4B beads (Amersham Phar-
macia Biotech). Pelleted beads were washed four times with RIPA buffer,
resuspended in electrophoresis sample buffer, boiled for 3 min, and pro-
teins were separated by 10% SDS-PAGE and blotted to Hybond
 
TM 
 
ECL
 
TM
 
nitrocellulose membrane (Amersham Pharmacia Biotech). Immunodetec-
tion was performed as described above.
 
Construction of DNA vectors
 
Expression vector pCMV-hPMCA 4b has been described previously
(pCMV-hPMCA4CI; Hammes et al., 1996). The point mutation Asp
 
672
 
→
 
Glu was inserted with the QuikChange
 
TM
 
 site-directed mutagenesis kit
(Stratagene) using the hPMCA 4b–modifying primers GTG GGC ATT GAG
GAG CCT GTG CGC CCA GAG GTG and CAC CTC TGG GCG CAC AGG
CTC CTC AAT GCC CAC. The pCMV-hPMCA4b cap vector was con-
structed by insertion of hPMCA 4b cDNA in BamHI-KpnI sites of
pcDNA3.1(
 
 
 
)/Myc-His vector (Invitrogen) and subsequent mutation of
Figure 4. Model for the regulation of NOS-I by PMCA 4b. NO 
production by NOS-I is reduced through Ca
2  extrusion via the 
PMCA, resulting in alteration of downstream signaling. 
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the hPMCA 4b stop codon to obtain a c-myc/6
 
 
 
His tag at the PMCA
COOH terminus. The constitutively active form of the PMCA 4b
(phPMCA4b[ct120]; Adamo et al., 1995), was a gift of E. Strehler (Mayo
Clinic, Rochester, NY). NOS-I expression plasmid (pCMV–NOS-I; Bren-
man et al., 1996) and pGST-PDZ (of NOS-I; Brenman et al., 1995) were a
gift of David S. Bredt (University of California, San Francisco, CA). The
NOS-III cDNA (Lamas et al., 1992; EMBL/GenBank/DDBJ accession no.
M89952) was cloned in the EcoRI site of pcDNA3 (Invitrogen), similar to
the NOS-I expression construct (see above). The 
 
 
 
NOS-I vector, coding for
NOS-I and lacking the PDZ domain, was constructed by excision of nucle-
otides 1–975 of the rat cDNA (numbering according to EMBL/GenBank/
DDBJ accession no. X59949), resulting in a truncated NOS-I, which is ex-
pressed in transfected cells and exhibits NO synthase activity.
 
Transfections and cGMP measurement
 
HEK293 and Neuro-2a cells (DSMZ) were grown in 90% DME/10% fetal
bovine serum/1
 
 
 
 nonessential amino acids (Sigma-Aldrich) to a density of
50–70% before transfection. HEK293 and neuro-2a cells were transfected
using the LipofectaminPLUS
 
TM
 
 system according to the manufacturer’s pro-
tocol (Life Technologies). After medium replacement cells were incubated
overnight. cGMP was measured using cGMP (low pH) colorimetric com-
petitive ELISA (R&D Systems). Cells were saturated with L-arginine (30
min, 1 mM) and, 5 min before lysis, nascent NO was stabilized by addition
of superoxide dismutase (100 U/ml culture medium; Roche Diagnostics).
In parallel, 3-isobutyl-1-methylxanthine (IBMX, 1 mM; Sigma-Aldrich) was
added to the culture 5 min before lysis (to inactivate phosphodiesterase ac-
tivity) and NO synthesis was induced by addition of 0.5 
 
 
 
M ionomycin 3
min before lysis. Subsequent determination of NO-dependent cGMP pro-
duction was estimated in relation to untransfected control cells.
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